Myron Kaplan Biography and Net Worth

Director of CorMedix

Myron Kaplan joined the Board of CorMedix in May 2016. Mr. Kaplan is a founding partner of Kleinberg, Kaplan, Wolff & Cohen, P.C., where he has practiced corporate and securities law for more than forty years. Among other responsibilities at the firm, Mr. Kaplan represents hedge funds and other companies in a broad spectrum of industries and works on financings, mergers and acquisitions, governance and compensation issues, distribution and license agreements and joint ventures. In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. He has served as a Director of a number of public companies and nonprofit organizations. Previously, he served as a member of the board of directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans World Airlines, Inc. and Kitty Hawk, Inc. Mr. Kaplan graduated from Columbia College and holds a Juris Doctor from Harvard Law School.

What is Myron Kaplan's net worth?: The estimated net worth of Myron Kaplan is at least $1.29 million as of October 23rd, 2025. Kaplan owns 201,034 shares of CorMedix stock worth more than $1,290,638 as of March 23rd. This net worth approximation does not reflect any other assets that Kaplan may own. Learn More about Myron Kaplan's net worth.
How do I contact Myron Kaplan?: The corporate mailing address for Kaplan and other CorMedix executives is 300 CONNELL DRIVE SUITE 4200, BERKELEY HEIGHTS NJ, 07922. CorMedix can also be reached via phone at (908) 517-9500 and via email at [email protected]. Learn More on Myron Kaplan's contact information.
Has Myron Kaplan been buying or selling shares of CorMedix?: Myron Kaplan has not been actively trading shares of CorMedix within the last three months. Most recently, on Thursday, October 23rd, Myron Kaplan bought 25,000 shares of CorMedix stock. The stock was acquired at an average cost of $11.02 per share, with a total value of $275,500.00. Following the completion of the transaction, the director now directly owns 201,034 shares of the company's stock, valued at $2,215,394.68. Learn More on Myron Kaplan's trading history.
Who are CorMedix's active insiders?: CorMedix's insider roster includes Alan Dunton (Director), Elizabeth Hurlburt (EVP), Myron Kaplan (Director), Steven Lefkowitz (Director), Erin Mistry (EVP), and Joseph Todisco (CEO). Learn More on CorMedix's active insiders.
Are insiders buying or selling shares of CorMedix?: During the last twelve months, CorMedix insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $275,500.00. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 253,997 shares worth more than $3,258,817.44. The most recent insider tranaction occured on December, 30th when Director Alan W Dunton sold 20,000 shares worth more than $260,000.00. Insiders at CorMedix own 3.1% of the company. Learn More about insider trades at CorMedix.
Information on this page was last updated on 12/30/2025.

Myron Kaplan Insider Trading History at CorMedix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/23/2025	Buy	25,000	$11.02	$275,500.00	201,034
5/17/2022	Buy	5,000	$3.78	$18,900.00	160,034
11/16/2021	Buy	10,000	$5.14	$51,400.00
5/17/2021	Buy	15,000	$6.03	$90,450.00	165,034
9/2/2020	Buy	15,300	$4.27	$65,331.00	150,034
5/15/2020	Buy	10,000	$3.85	$38,500.00	119,734
9/30/2019	Buy	5,000	$6.81	$34,050.00	109,734
3/22/2019	Buy	20,000	$1.65	$33,000.00	493,666
12/14/2018	Buy	50,000	$1.47	$73,500.00	431,166
11/23/2018	Buy	50,000	$1.30	$65,000.00	371,166
8/17/2017	Buy	80,000	$0.40	$32,000.00	180,000
8/14/2017	Buy	50,000	$0.35	$17,500.00	100,000

Myron Kaplan Buying and Selling Activity at CorMedix

CorMedix Company Overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Today's Range

Now: $6.42

$6.28

$6.51

50 Day Range

MA: $7.14

$6.25

$8.17

2 Week Range

Now: $6.42

$5.60

$17.43

Volume

1,428,271 shs

Average Volume

2,607,843 shs

Market Capitalization

$507.50 million

P/E Ratio

3.21

Dividend Yield

N/A

Beta

1.31